Mosapride is novel prokinetic agent which seems to exert its action via a high affinity and specifity for 5-HT4 receptor. In addition the principal metabolite has high affinity for 5-HT3 receptors and has proved to be potent 5-HT3 antagonist. Mosapride has been used to treat gastroesophageal reflux disease, chronic gastritis, nonulcer dyspepsia and diabetic gastropathy. In the present study, an attempt has been made to formulate orodispersible tablets of Mosapride Citrate Dihydrate. The other objective of the study was to evaluate the performance of three different classes of superdisintegrants which are croscarmellose Sodium (Ac-Di-Sol), crospovidone (Polyplasdone XL), sodium starch glycolate (Primojel) in promoting disintegration and dissolution of Mosapride citrate dihydrate orodispersible tablets. At the optimum concentrations of 2% & 4% of selected superdisintegrants, their effect in the orodispersible tablet on the in vitro disintegration & in vitro dissolution was evaluated. It was concluded that, the formulation of Mosapride citrate dihydrate orodispersible tablets was made with functionality evaluation of selected superdisintegrants.